Ticker Details
Kyverna Therapeutics, Inc. Common Stock
IPO Date:	February 9, 2024
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$520.72M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.37 | 4.77%
Avg Daily Range (30 D):	$0.30 | 3.66%
Avg Daily Range (90 D):	$0.34 | 3.68%

Institutional Daily Volume
Avg Daily Volume:	.58M
Avg Daily Volume (30 D):	.83M
Avg Daily Volume (90 D):	.92M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	75
Avg Trade Size (Sh.) (90 D):	73

Institutional Trades
Total Institutional Trades:	196
Avg Institutional Trade:	$1.75M
Avg Institutional Trade (30 D):	$.73M
Avg Institutional Trade (90 D):	$1.67M
Avg Institutional Trade Volume:	.17M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.1M
Avg Closing Trade (30 D):	$.73M
Avg Closing Trade (90 D):	$1.77M
Avg Closing Volume:	226.52K

News

Jun 10, 2026 @ 5:00 PM Lupus Nephritis Clinical Trial Landscape Becomes I... Source: Delveinsight

Jun 8, 2026 @ 6:34 PM Kyverna Therapeutics vs. Vertex Pharmaceuticals: W... Source: Brendan Coffey

May 14, 2026 @ 12:00 PM Kyverna Therapeutics to Present at Upcoming Invest... Source: Na

Apr 21, 2026 @ 10:45 PM Kyverna Presents Registrational Trial Primary Anal... Source: Na

Feb 24, 2026 @ 1:00 PM Kyverna Therapeutics Appoints Biotech Leaders Srav... Source: Na

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.93	$-.63	$-.66
Diluted EPS	$-2.93	$-.63	$-.66
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-152.64M	$-38.32M	$-39.73M
Operating Income / Loss	$-158.93M	$-39.56M	$-41.37M
Cost of Revenue
Net Cash Flow	$-21.63M	$-.39M	$-91.9M
PE Ratio